Title:
DRUG AND METHOD FOR NUCLEOSIDE (ACID) DRUG THERAPY OF LIMITING CHRONIC HEPATITIS B
Document Type and Number:
WIPO Patent Application WO/2023/138696
Kind Code:
A1
Abstract:
The present invention relates to a drug and method for nucleoside (acid) drug therapy of limiting chronic hepatitis B, in particular to the use of an HBV virus entry inhibitor and an optional immunomodulator in the preparation of a drug or kit for nucleoside (acid) drug therapy of limiting or terminating chronic hepatitis B. By using the method provided by the invention, after administering the nucleoside (acid) drug, the HBV virus entry inhibitor and the optional immunomodulator for combined therapy for a certain course of treatment, the drug can be completely stopped, and the patient does not need to continue to accept NAs treatment.
Inventors:
LIU HONGLI (CN)
Application Number:
PCT/CN2023/076223
Publication Date:
July 27, 2023
Filing Date:
February 15, 2023
Export Citation:
Assignee:
SHANGHAI HEP PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K45/06; A61K31/513; A61K31/522; A61K31/675; A61K31/7072; A61K38/16; A61K38/21; A61P1/16; A61P31/14; A61P31/20
Domestic Patent References:
| WO2016055534A2 | 2016-04-14 | |||
| WO2019080919A1 | 2019-05-02 | |||
| WO2021130270A1 | 2021-07-01 |
Foreign References:
| CN101970464A | 2011-02-09 | |||
| CN102675430A | 2012-09-19 | |||
| EP3865489A1 | 2021-08-18 |
Other References:
KANG CONNIE, SYED YAHIYA: "Bulevirtide: First Approval", DRUGS, ADIS INTERNATIONAL LTD., NZ, vol. 80, no. 15, 14 September 2020 (2020-09-14), NZ , pages 1601 - 1605, XP009547809, ISSN: 0012-6667, DOI: 10.1007/s40265-020-01400-1
Attorney, Agent or Firm:
SHANGHAI PATENT & TRADEMARK LAW OFFICE , LLC (CN)
Download PDF: